1. Injection of paternal leukocytes (paternal white cell immunization or paternal cell alloimmunization) 2. Intravenous immunoglobulin (IVIG) therapy B. The following tests/studies are considered experimental and investigational and are not covered benefits:
1. Reproductive immunophenotype (CD3+, CD4+, CD5+, CD8+, CD16+, CD19+, CD56+) 2. Cytokine polymorphisms analysis (Th1/Th2 intra-cellular cytokine ratio) 3. Natural Killer (NK) cell testing
II. MEDICAL NECESSITY REVIEW

Required
Not Required Not Applicable
III. APPLICATION TO PRODUCTS
Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable. Special Notes: This policy is renamed from the previous "Immunotherapy for Habitual Abortions"
IV. DESCRIPTION
Recurrent spontaneous abortion (RSA) is defined as 3 or more consecutive pregnancies with the same partner which end in miscarriage before 20 weeks gestation. One theory about RSA is that the mother forms an allergic response to the placenta or other fetal tissue, and that the mother could be desensitized by giving her small doses of tissue from the father or from other's reproductive tissue. Primarily, two forms of immunotherapy have been attempted for RSA: injection of paternal leukocytes and intravenous immunoglobulin. The American College of Obstetricians and Gynecologists (2001) considers these two therapies as ineffective. 
V. CODING INFORMATION
